Label Changes for:

Uroxatral (alfuzosin hydrochloride) extended-release tablets 

May 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

May 2013

ADVERSE REACTIONS

Post-Marketing Experience
  • add to Blood and lymphatic system disorders: thrombocytopenia

 

December 2010

 

USE IN SPECIFIC POPULATIONS

Pediatric Use
  • Uroxatral is not indicated for use in the pediatric population.
  • Efficacy of alfuzosin hydrochloride was not demonstrated in a randomized, double-blind, placebo-controlled, efficacy and safety trial conducted in 172 patients ages 2 to 16 years with elevated detrusor leak point pressure (LPP 40 cm H2O) of neurologic origin treated with alfuzosin hydrochloride using pediatric formulations. The trial included a 12-week efficacy phase followed by a 40-week safety extension period. No... 
  • Alfuzosin hydrochloride was not studied in patients below the age of 2.

 

Hide
(web4)